Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University College Dublin
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06062277CT.gov COlchicine iN Circulating Inflammatory Markers After StrokE (CONCISE) | — | Unknown | — | — | — |
NCT05476991CT.gov Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Atherosclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Colchicinum (this asset) | University College Dublin | P3 | BB · 64 |
| Aspirin | Rajaie Cardiovascular Medical and Research Center | P4 | BBB |
| Simvastatin | Northern California Institute of Research and Education | P4 | BBB |
| Atorvastatin | Erasmus Medical Center | P4 | BB |
| Rosuvastatin | Emory University | P4 | BB |
| Ezetimibe | paresh Dandona | P4 | BB |
| Cilostazol | Asan Medical Center | P4 | BB |
| Clopidogrel | Ewha Womans University Seoul Hospital | P4 | BB |
| Testosterone Undecylate | Brigham and Women's Hospital | P4 | BB |
+37 more in the Atherosclerosis cohort
Other indications for Colchicinum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
| Fibrotic Liver Disease | — | P4 | BB · 69 |
| Hepatitis C Virus Infection | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Colchicinum in Atherosclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/colchicinum-atherosclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →